Advertisement

Mesenchymal Stem/Stromal Cell Therapy for Bronchopulmonary Dysplasia in the Neonatal Intensive Care Unit

  • Amélie CollinsEmail author
Neonatology (C Juliano, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Neonatology

Abstract

Purpose of Review

Clinical trials of mesenchymal stem/stromal cell (MSC) therapy for bronchopulmonary dysplasia (BPD) are already underway. A thorough understanding of the preclinical work that underpins these trials is critical for neonatal practitioners to properly evaluate them.

Recent Findings

The more significant advances have been in investigating the mechanisms of action by which MSCs are thought to ameliorate BPD, and the recognition that this therapeutic effect is largely contained within the non-cellular exosome fraction of MSCs.

Summary

In rodent hyperoxia models of BPD, MSCs have a pro-angiogenic effect mediated largely by vascular endothelial growth factor (VEGF) and shift the balance of endogenous lung cells from a pro-inflammatory to a pro-healing phenotype. MSC-derived exosomes can recapitulate these effects.

Keywords

Mesenchymal stem cells Mesenchymal stromal cells Bronchopulmonary dysplasia Rodent hyperoxia models Neonatal intensive care unit 

Notes

Acknowledgments

The author would like to thank Jessica Shui for her contributions to earlier versions of this work, and Thomas Hooven for critical review of the manuscript.

Compliance with Ethical Standards

Conflict of Interest

The author declares that there is no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Stoll BJ, Hansen NI, Bell EF, Walsh MC, Carlo WA, Shankaran S, et al. Trends in care practices, morbidity, and mortality of extremely preterm neonates, 1993-2012. JAMA. 2015;314:1039–51.CrossRefGoogle Scholar
  2. 2.
    Michael Z, Spyropoulos F, Ghanta S, Christou H. Bronchopulmonary dysplasia: an update of current pharmacologic therapies and new approaches. Clin Med Insights Pediatr. 2018;12:117955651881732.CrossRefGoogle Scholar
  3. 3.
    Friedenstein AJ, Chailakhjan RK, Lalykina KS. The development of fibroblast colonies in monolayer cultures of guinea-pig bone marrow and spleen cells. Cell Tissue Kinet. 1970;3:393–403.Google Scholar
  4. 4.
    Friedenstein AJ, Petrakova KV, Kurolesova AI, Frolova GP. Heterotopic of bone marrow. Analysis of precursor cells for osteogenic and hematopoietic tissues. Transplantation. 1968;6:230–47.CrossRefGoogle Scholar
  5. 5.
    Friedenstein AJ, Gorskaja JF, Kulagina NN. Fibroblast precursors in normal and irradiated mouse hematopoietic organs. Exp Hematol. 1976;4:267–74.Google Scholar
  6. 6.
    • Squillaro T, Peluso G, Galderisi U. Clinical trials with mesenchymal stem cells: an update. Cell Transplant. 2016;25:829–48. Reference 6 is a good overview of clinical application of MSCs across many disciplines. CrossRefGoogle Scholar
  7. 7.
    Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause DS, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006;8:315–7.CrossRefGoogle Scholar
  8. 8.
    Caplan AI. Mesenchymal stem cells: time to change the name! Stem Cells Transl Med. 2017;6:1445–51.CrossRefGoogle Scholar
  9. 9.
    • Prockop DJ. The exciting prospects of new therapies with mesenchymal stromal cells. Cytotherapy. 2017;19:1–8. Reference 9 is a excellent general reviews of MSC applications.CrossRefGoogle Scholar
  10. 10.
    • Keating A. Mesenchymal stromal cells: new directions. Cell Stem Cell. 2012;10:709–16. Reference 10 is a excellent general reviews of basic mechanisms. CrossRefGoogle Scholar
  11. 11.
    Kourembanas S. Exosomes: vehicles of intercellular signaling, biomarkers, and vectors of cell therapy. Annu Rev Physiol. 2015;77:13–27.CrossRefGoogle Scholar
  12. 12.
    Lai RC, Yeo RWY, Lim SK. Mesenchymal stem cell exosomes. Semin Cell Dev Biol. 2015;40:82–8.CrossRefGoogle Scholar
  13. 13.
    Jobe AH. What is BPD in 2012 and what will BPD become? Early Hum Dev. 2012;88:S27–8.CrossRefGoogle Scholar
  14. 14.
    Möbius MA, Thébaud B. Bronchopulmonary dysplasia: where have all the stem cells gone? Chest. 2017;152:1043–52.CrossRefGoogle Scholar
  15. 15.
    Popova AP, Bozyk PD, Bentley JK, Linn MJ, Goldsmith AM, Schumacher RE, et al. Isolation of tracheal aspirate mesenchymal stromal cells predicts bronchopulmonary dysplasia. Pediatrics. 2010;126:e1127–33.CrossRefGoogle Scholar
  16. 16.
    Tropea KA, Leder E, Aslam M, Lau AN, Raiser DM, Lee J-H, et al. Bronchioalveolar stem cells increase after mesenchymal stromal cell treatment in a mouse model of bronchopulmonary dysplasia. Am J Physiol Cell Mol Physiol. 2012;302:L829–37.CrossRefGoogle Scholar
  17. 17.
    Berger J, Bhandari V. Animal models of bronchopulmonary dysplasia. The term mouse models. Am J Physiol Cell Mol Physiol. 2014;307:L936–47.CrossRefGoogle Scholar
  18. 18.
    O’Reilly M, Thébaud B. Animal models of bronchopulmonary dysplasia. The term rat models. Am J Physiol Cell Mol Physiol. 2014;307:L948–58.CrossRefGoogle Scholar
  19. 19.
    •• Aslam M, Baveja R, Liang OD, Fernandez-Gonzalez A, Lee C, Mitsialis SA, et al. Bone marrow stromal cells attenuate lung injury in a murine model of neonatal chronic lung disease. Am J Respir Crit Care Med. 2009;180:1122–30. Reference 19 is one of the original studies to identify a beneficial effect of MSCs on experimental BPD. CrossRefGoogle Scholar
  20. 20.
    •• van Haaften T, Byrne R, Bonnet S, Rochefort GY, Akabutu J, Bouchentouf M, et al. Airway delivery of mesenchymal stem cells prevents arrested alveolar growth in neonatal lung injury in rats. Am J Respir Crit Care Med. 2009;180:1131–42. Reference 20 is one of the original studies to identify a beneficial effect of MSCs on experimental BPD. CrossRefGoogle Scholar
  21. 21.
    Mei Y, Chen C, Dong H, Zhang W, Wang Y, Chi M, et al. Treatment of hyperoxia-induced lung injury with lung mesenchymal stem cells in mice. Stem Cells Int. 2018;2018:1–8.CrossRefGoogle Scholar
  22. 22.
    Ahn SY, Chang YS, Sung DK, Yoo HS, Sung SI, Choi SJ, et al. Cell type–dependent variation in paracrine potency determines therapeutic efficacy against neonatal hyperoxic lung injury. Cytotherapy. 2015;17:1025–35.CrossRefGoogle Scholar
  23. 23.
    Sammour I, Somashekar S, Huang J, Batlahally S, Breton M, Valasaki K, et al. The effect of gender on mesenchymal stem cell (MSC) efficacy in neonatal Hyperoxia-induced lung injury. Kirchmair R, editor. PLoS One. 2016;11:e0164269.CrossRefGoogle Scholar
  24. 24.
    Liu L, Mao Q, Chu S, Mounayar M, Abdi R, Fodor W, et al. Intranasal versus intraperitoneal delivery of human umbilical cord tissue–derived cultured mesenchymal stromal cells in a murine model of neonatal lung injury. Am J Pathol. 2014;184:3344–58.CrossRefGoogle Scholar
  25. 25.
    Sung DK, Chang YS, Ahn SY, Sung SI, Yoo HS, Choi SJ, et al. Optimal route for human umbilical cord blood-derived mesenchymal stem cell transplantation to protect against neonatal hyperoxic lung injury: gene expression profiles and histopathology. Almeida-Porada GD, editor. PLoS One. 2015;10:e0135574.CrossRefGoogle Scholar
  26. 26.
    • Chang YS, Choi SJ, Ahn SY, Sung DK, Sung SI, Yoo HS, et al. Timing of umbilical cord blood derived mesenchymal stem cells transplantation determines therapeutic efficacy in the neonatal hyperoxic lung injury. Covas DT, editor. PLoS One. 2013;8:e52419. Careful analysis of timing of MSC administration with relation to possible mechanism. CrossRefGoogle Scholar
  27. 27.
    Zhang Z, Sun C, Wang J, Jiang W, Xin Q, Luan Y. Timing of erythropoietin modified mesenchymal stromal cell transplantation for the treatment of experimental bronchopulmonary dysplasia. J Cell Mol Med. 2018;22:5759–63.CrossRefGoogle Scholar
  28. 28.
    Gülaşı S, Atıcı A, Yılmaz ŞN, Polat A, Yılmaz M, Laçin MT, et al. Mesenchymal stem cell treatment in hyperoxia-induced lung injury in newborn rats. Pediatr Int. 2016;58:206–13.CrossRefGoogle Scholar
  29. 29.
    Luan Y, Zhang L, Chao S, Liu X, Li K, Wang Y, et al. Mesenchymal stem cells in combination with erythropoietin repair hyperoxia-induced alveoli dysplasia injury in neonatal mice via inhibition of TGFb-1 signaling. Oncotarget. 2016;7:47082–94.Google Scholar
  30. 30.
    Zhang Z-H, Pan Y-Y, Jing R-S, Luan Y, Zhang L, Sun C, et al. Protective effects of BMSCs in combination with erythropoietin in bronchopulmonary dysplasia-induced lung injury. Mol Med Rep. 2016;14:1302–8.CrossRefGoogle Scholar
  31. 31.
    Chen C-M, Chou H-C, Lin W, Tseng C. Surfactant effects on the viability and function of human mesenchymal stem cells: in vitro and in vivo assessment. Stem Cell Res Ther. 2017;8:180.CrossRefGoogle Scholar
  32. 32.
    Luan Y, Ding W, Ju Z-Y, Zhang Z-H, Zhang X, Kong F. Bone marrow-derived mesenchymal stem cells protect against lung injury in a mouse model of bronchopulmonary dysplasia. Mol Med Rep. 2015;11:1945–50.CrossRefGoogle Scholar
  33. 33.
    Chou H-C, Li Y-T, Chen C-M. Human mesenchymal stem cells attenuate experimental bronchopulmonary dysplasia induced by perinatal inflammation and hyperoxia. Am J Transl Res. 2016;8:342–53.Google Scholar
  34. 34.
    Chen C-M, Lin W, Huang L-T, Chou H-C. Human mesenchymal stem cells ameliorate experimental pulmonary hypertension induced by maternal inflammation and neonatal hyperoxia in rats. Oncotarget. 2017;8:82366–75.Google Scholar
  35. 35.
    Hou C, Peng D, Gao L, Tian D, Dai J, Luo Z, et al. Human umbilical cord-derived mesenchymal stem cells protect from hyperoxic lung injury by ameliorating aberrant elastin remodeling in the lung of O2-exposed newborn rat. Biochem Biophys Res Commun. 2018;495:1972–9.CrossRefGoogle Scholar
  36. 36.
    • Reiter J, Drummond S, Sammour I, Huang J, Florea V, Dornas P, et al. Stromal derived factor-1 mediates the lung regenerative effects of mesenchymal stem cells in a rodent model of bronchopulmonary dysplasia. Respir Res. 2017;18:137. Good mechanistic study examining effects of SDF-1 in MSC therapy. CrossRefGoogle Scholar
  37. 37.
    Martinez FO, Gordon S. The M1 and M2 paradigm of macrophage activation: time for reassessment. F1000Prime Rep. 2014;6:13.CrossRefGoogle Scholar
  38. 38.
    •• Al-Rubaie A, Wise AF, Sozo F, De Matteo R, Samuel CS, Harding R, et al. The therapeutic effect of mesenchymal stem cells on pulmonary myeloid cells following neonatal hyperoxic lung injury in mice. Respir Res. 2018;19:114. Interesting investigation of lung alveolar phenotype in experimental BPD and impact of MSCs. CrossRefGoogle Scholar
  39. 39.
    Healy AM, Morgenthau L, Zhu X, Farber HW, Cardoso WV. VEGF is deposited in the subepithelial matrix at the leading edge of branching airways and stimulates neovascularization in the murine embryonic lung. Dev Dyn. 2000;219:341–52.CrossRefGoogle Scholar
  40. 40.
    Bhatt AJ, Pryhuber GS, Huyck H, Watkins RH, Metlay LA, Maniscalco WM. Disrupted pulmonary vasculature and decreased vascular endothelial growth factor, Flt-1, and TIE-2 in human infants dying with bronchopulmonary dysplasia. Am J Respir Crit Care Med. 2001;164:1971–80.CrossRefGoogle Scholar
  41. 41.
    •• Chang YS, Ahn SY, Jeon HB, Sung DK, Kim ES, Sung SI, et al. Critical role of vascular endothelial growth factor secreted by mesenchymal stem cells in hyperoxic lung injury. Am J Respir Cell Mol Biol. 2014;51:391–9. Good mechanistic study examining the effects of manipulating VEGF levels. CrossRefGoogle Scholar
  42. 42.
    Jiménez J, Lesage F, Richter J, Nagatomo T, Salaets T, Zia S, et al. Upregulation of vascular endothelial growth factor in amniotic fluid stem cells enhances their potential to attenuate lung injury in a preterm rabbit model of bronchopulmonary dysplasia. Neonatology. 2018;113:275–85.CrossRefGoogle Scholar
  43. 43.
    Braun RK, Chetty C, Balasubramaniam V, Centanni R, Haraldsdottir K, Hematti P, et al. Intraperitoneal injection of MSC-derived exosomes prevent experimental bronchopulmonary dysplasia. Biochem Biophys Res Commun. 2018;503:2653–8.CrossRefGoogle Scholar
  44. 44.
    •• Chaubey S, Thueson S, Ponnalagu D, Alam MA, Gheorghe CP, Aghai Z, et al. Early gestational mesenchymal stem cell secretome attenuates experimental bronchopulmonary dysplasia in part via exosome-associated factor TSG-6. Stem Cell Res Ther. 2018;9:173. Thorough evaluation of role of TSG-6 in MSC exosomes and their impact on experimental BPD. CrossRefGoogle Scholar
  45. 45.
    Porzionato A, Zaramella P, Dedja A, Guidolin D, Van Wemmel K, Macchi V, et al. Intratracheal administration of clinical-grade mesenchymal stem cell-derived extracellular vesicles reduces lung injury in a rat model of bronchopulmonary dysplasia. Am J Physiol Cell Mol Physiol. 2019;316:L6–19.CrossRefGoogle Scholar
  46. 46.
    • Ahn SY, Park WS, Kim YE, Sung DK, Sung SI, Ahn JY, et al. Vascular endothelial growth factor mediates the therapeutic efficacy of mesenchymal stem cell-derived extracellular vesicles against neonatal hyperoxic lung injury. Exp Mol Med. 2018;50:26. Good study demonstrating that VEGF in MSC exosomes has significant beneficial effect on experimental BPD. CrossRefGoogle Scholar
  47. 47.
    •• Willis GR, Fernandez-Gonzalez A, Anastas J, Vitali SH, Liu X, Ericsson M, et al. Mesenchymal stromal cell exosomes ameliorate experimental bronchopulmonary dysplasia and restore lung function through macrophage immunomodulation. Am J Respir Crit Care Med. 2018;197:104–16. Excellent study linking MSC exosomes and modulation of lung macrophage phenotypes. CrossRefGoogle Scholar
  48. 48.
    Syed MA, Bhandari V. Hyperoxia exacerbates postnatal inflammation-induced lung injury in neonatal BRP-39 null mutant mice promoting the M1 macrophage phenotype. Mediat Inflamm. 2013;2013:1–12.CrossRefGoogle Scholar
  49. 49.
    Mittal M, Tiruppathi C, Nepal S, Zhao Y-Y, Grzych D, Soni D, et al. TNFα-stimulated gene-6 (TSG6) activates macrophage phenotype transition to prevent inflammatory lung injury. Proc Natl Acad Sci. 2016;113:E8151–8.CrossRefGoogle Scholar
  50. 50.
    • Chang YS, Ahn SY, Yoo HS, Sung SI, Choi SJ, W Il O, et al. Mesenchymal stem cells for bronchopulmonary dysplasia: phase 1 dose-escalation clinical trial. J Pediatr. 2014;164:966–972.e6. The first and only clinical trial of MSCs in human infants. CrossRefGoogle Scholar
  51. 51.
    Ahn SY, Chang YS, Kim JH, Sung SI, Park WS. Two-year follow-up outcomes of premature infants enrolled in the phase I trial of mesenchymal stem cells transplantation for bronchopulmonary dysplasia. J Pediatr. 2017;185:49–54.e2.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Division of Neonatology-Perinatology, Department of PediatricsColumbia University Irving Medical CenterNew YorkUSA

Personalised recommendations